Challenges in Glycemic Monitoring: Undetectable HbA1c Level in an Asymptomatic Patient with Hemoglobin E and Beta-Thalassemia Minor
A Case Report
DOI:
https://doi.org/10.15605/jafes.041.02.6223Keywords:
hemoglobinopathy, HbA1c, HPLC, electrophoresisAbstract
Glycated hemoglobin (HbA1c) is a laboratory examination recommended by the American Diabetes Association to monitor blood glucose levels in patients with diabetes mellitus. This gold standard method for testing HbA1c uses high-performance liquid chromatography (HPLC). One advantage of HbA1c testing with HPLC is the ability to detect Hb variants or hemoglobinopathies, although HbA1c results may become irrelevant in such conditions. A 49-year-old female patient came to the Ophthalmology Outpatient Clinic of Dr. Soetomo Hospital due to visual impairment in both eyes and plans for cryotherapy surgery. In preparation for the surgery, laboratory tests were performed with results of haemoglobin 12.1 g/dL, mean corpuscular volume 58.9 fL, mean corpuscular haemoglobin 19.3 pg, leukocytes 13,370/uL, platelets 399,000/uL and random blood glucose 127 mg/dL; however, HbA1c was not detected. In the HbA1c test, a 93.7% window variant was obtained. Based on blood smear evaluation, there was hypochromic microcytic anisopoikilocytosis with target cells. The electrophoresis results revealed HbA 0.7%, HbF 0.6%, HbE 94.9% and HbA2 4.7%, indicating the presence of beta thalassemia with hemoglobinopathy E. The diagnosis of hemoglobinopathy E is based on a complete blood count, peripheral blood smear and haemoglobin electrophoresis. HbA1c examination by HPLC can yield undetectable HbA1c levels in hemoglobinopathies. Monitoring blood glucose levels in such cases is also irrelevant when using HbA1c, because red blood cells have a shorter lifespan in the presence of Hb variants. Glucose monitoring in this condition can be done by periodic glucose examination, fructosamine, or glycated albumin. The HbA1c test cannot be used as a marker of glucose control in patients with hemoglobinopathy E.
Downloads
References
1. American Diabetes Association. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care. 2024;47(1):S20-42. https://doi.org/10.2337/dc24-S002
2. Keohane EM, Smith LJ, Walenga JM. Rodak’s hematology clinical principles and applications, 5th ed. Elsevier; 2016. https://labscientists.wordpress.com/wp-content/uploads/2019/04/rodaks-hematology-5e-2016-unitedvrg-.pdf
3. Khera R, Singh T, Khuana N, Gupta N, Dubey AP. HPLC in characterization of hemoglobin profile in thalassemia syndromes and hemoglobinopathies: A clinicohematological correlation. Indian J Hematol Blood Transfus. 2015;31(1):110-5. https://pubmed.ncbi.nlm.nih.gov/25548455 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275515 https://doi.org/10.1007/s12288-014-0409-x
4. Kementerian Kesehatan Republik Indonesia. Putuskan Mata Rantai Talasemia, untuk Indonesia Lebih Sehat; 2019.
5. Wahidiyat PA, Sari TT, Rahmartani LD, et al. Thalassemia in Indonesia. Hemoglobin. 2022;46(1):39–44. https://pubmed.ncbi.nlm.nih.gov/35950580 https://doi.org/10.1080/03630269.2021.2023565
6. Octavius GS, Daleni VA, Sagala YDS. An insight into Indonesia’s progress for newborn screening program: What is currently going on. Heliyon. 2024;10(13):e33479. https://pubmed.ncbi.nlm.nih.gov/39035496 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259875 https://doi.org/10.1016/j.heliyon.2024.e33479
7. Trent, RJA. Diagnosis of the haemoglobinopathies. Clin Biochem Rev. 2006;27(1):27-38. https://pubmed.ncbi.nlm.nih.gov/16886045 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1390791
8. Aktas A, Ipek BO, Dikker O. Unmeasurable HbA1c result due to hemoglobinopathy. Int J Med Biochem. 2024;7(1):41-4. https://doi.org/10.14744/ijmb.2023.59480
9. Smaldone A. Glycemic control and hemoglobinopathy: When A1c may not be reliable. Diabetes Spectrum. 2008;21(1):46-9. https://doi.org/10.2337/diaspect.21.1.46
10. Bain BJ, Bates I, Laffan MA. Dacie and Lewis Practical Haematology, 12th ed. Elsevier; 2016.
11. Bhattarai U, Adhikari D, Gautam A, Anand A, Shah B, Sharma SK. Severe homozygous HbE disease: The first case report from Nepal. Oxf Med Case Reports. 2023;2023(6):omad062. https://pubmed.ncbi.nlm.nih.gov/37377720 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292636 https://doi.org/10.1093/omcr/omad062
12. Basumatary N, Baruah D, Sarma PK, Sarma J. A case report of co-occurrence of hemoglobinopathy EE and glucose-6-phosphate dehydrogenase A+ variant. Biomed Biotechnol Res J. 2023;7(4):646-8. https://doi.org/10.4103/bbrj.bbrj_228_23
13. Yedla N, et al. Hemoglobin E disease and glycosylated hemoglobin. Indian J Endocrinol Metab. 2015;19(5):683-5. https://pubmed.ncbi.nlm.nih.gov/26425484 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566355 https://doi.org/10.4103/2230-8210.163211
14. Sri VLP, Sreeja C, Muthukumar RS, Nachiamma N, Jayaraj M, Priya AHH. HBE homozygous haemoglobinopathy – Fortuitous finding. J Oral Maxillofac Pathol. 2022;26(4):580-2. https://pubmed.ncbi.nlm.nih.gov/37082065 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112082 https://doi.org/10.4103/jomfp.jomfp_98_22
15. Gargallo MA, González FA, Villegas A. Abnormally low HbA1c secondary to hemoglobin J-Baltimore [beta 16(A13) GlyAsp]. Family study. Endocrinol Nutr. 2010;57(2):83-5. https://pubmed.ncbi.nlm.nih.gov/20206586 https://doi.org/10.1016/j.endonu.2010.01.004
16. Mitchai M, Suwansaksri N, Seanseeha S, et al. Misleading HbA1c measurement in diabetic patients with hemoglobin variants. Med Sci (Basel). 2021;9(2):43. https://pubmed.ncbi.nlm.nih.gov/34200315 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293317 https://doi.org/10.3390/medsci9020043
17. Dupuy AM, Cristol JP, Bargnoux AS, et al. The pivotal role of HbA1c assay to detect hemoglobinopathies: A 5-year observational retrospective study in the population of Southern France. Health Sci Rep. 2023;6(7):e1270. https://pubmed.ncbi.nlm.nih.gov/37465239 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350560 https://doi.org/10.1002/hsr2.1270
18. Chung K, Huang N. Undetectable glycated hemoglobin (HbA1c): An interesting case. Clin Diabetol. 2023;12(2):135-6. https://doi.org/10.5603/DK.a2023.0004
19. Hegde SN, Srikousthubha MS, Anupama YJ. A case of undetectable glycated hemoglobin (HbA1c). QJM. 2018;111(8):567-8. https://pubmed.ncbi.nlm.nih.gov/29660089 https://doi.org/10.1093/qjmed/hcy080
20. Liddy AM, Grundy S, Sreenan S, Tormey W. Impact of haemoglobin variants on use of the haemoglobin A1c for the diagnosis and monitoring of diabetes: A contextualised review. Ir J Med Sci. 2022;192(1):169-76. https://pubmed.ncbi.nlm.nih.gov/35362846 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892076 https://doi.org/10.1007/s11845-022-02967-2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dita Prawitasari, Syaifuddin Zuhri, Muhamad Fuadi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
